Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers-Reference-Cited by-同舟云学术

Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers

Published:2018-11 Issue:2 Volume: Page:1-12
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Offin Michael¹,Somwar Romel¹,Rekhtman Natasha¹,Benayed Ryma¹,Chang Jason C.¹,Plodkowski Andrew¹,Lui Allan J.W.¹,Eng Juliana¹,Rosenblum Marc¹,Li Bob T.¹,Riely Gregory J.¹,Rudin Charles M.¹,Kris Mark G.¹,Travis William¹,Drilon Alexander¹,Arcila Maria E.¹,Ladanyi Marc¹,Yu Helena A.¹

Affiliation:

1. All authors, Memorial Sloan Kettering Cancer Center; Michael Offin, Juliana Eng, Bob T. Li, Gregory J. Riely, Charles M. Rudin, Mark G. Kris, Alexander Drilon, and Helena A. Yu, Weill Cornell Medical College, New York, NY; and Allan J.W. Jui, The Chinese University of Hong Kong, Sha Tin New Town, Hong Kong Special Administrative Region, China.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.18.00126

Reference24 articles.

1. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

2. Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

3. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

4. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

5. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer;JCO Precision Oncology;2024-08

2. Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer;Frontiers in Pharmacology;2024-07-29

3. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers;Nature Communications;2024-06-14

4. Expanding the Reach of Personalized Medicine in Cancer Care: Current Progress and Future Directions of JCO Precision Oncology;JCO Precision Oncology;2024-05

5. Résistance aux anti-EGFR via l’acquisition successive et cumulée de deux nouvelles addictions oncogénique BRAF et ALK;Revue des Maladies Respiratoires;2024-05